MX9505181A - Utilizacion de un antagonista de la substancia p en una composicion farmaceutica para tratar desordenes de la piel de origen neurogenico. - Google Patents

Utilizacion de un antagonista de la substancia p en una composicion farmaceutica para tratar desordenes de la piel de origen neurogenico.

Info

Publication number
MX9505181A
MX9505181A MX9505181A MX9505181A MX9505181A MX 9505181 A MX9505181 A MX 9505181A MX 9505181 A MX9505181 A MX 9505181A MX 9505181 A MX9505181 A MX 9505181A MX 9505181 A MX9505181 A MX 9505181A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
utilization
skin disorders
substance antagonist
neurogenic skin
Prior art date
Application number
MX9505181A
Other languages
English (en)
Inventor
Olivier De Lacharriere
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9469929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9505181(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Publication of MX9505181A publication Critical patent/MX9505181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La invencion se refiere al uso de un antagonista de sustancia P para la preparacion de una composicion farmacéutica, en particular para aplicacion topica, para tratar líquenes, prurigo, toxicoderma pruriginosa y prurito severo o grave de origen neurogénico.
MX9505181A 1994-12-19 1995-12-11 Utilizacion de un antagonista de la substancia p en una composicion farmaceutica para tratar desordenes de la piel de origen neurogenico. MX9505181A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9415251A FR2728265A1 (fr) 1994-12-19 1994-12-19 Utilisation d'un antagoniste de substance p dans une composition pharmaceutique

Publications (1)

Publication Number Publication Date
MX9505181A true MX9505181A (es) 1997-02-28

Family

ID=9469929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9505181A MX9505181A (es) 1994-12-19 1995-12-11 Utilizacion de un antagonista de la substancia p en una composicion farmaceutica para tratar desordenes de la piel de origen neurogenico.

Country Status (14)

Country Link
US (2) US5679360A (es)
EP (1) EP0717997B1 (es)
JP (1) JPH08208506A (es)
AR (1) AR000509A1 (es)
AT (1) ATE204177T1 (es)
BR (1) BR9505382A (es)
CA (1) CA2165520C (es)
DE (1) DE69522188T2 (es)
ES (1) ES2160680T3 (es)
FR (1) FR2728265A1 (es)
HU (1) HU218921B (es)
MX (1) MX9505181A (es)
PL (1) PL311916A1 (es)
RU (1) RU2146519C1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2719474B1 (fr) * 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2738742B1 (fr) * 1995-09-19 1997-11-14 Oreal Utilisation d'au moins une eau thermale de vichy en tant qu'antagoniste de substance p
FR2742054B1 (fr) * 1995-12-06 1998-01-09 Synthelabo Compositions pharmaceutiques contenant un agent anti-inflammatoire et des ceramides vegetales
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
FR2768624B1 (fr) * 1997-09-25 1999-11-12 Oreal Utilisation d'un inhibiteur d'acides amines excitateurs dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
US6214318B1 (en) 1997-10-02 2001-04-10 Oms Holdings Llc Aerosol ointment compositions for topical use
DE19902530C1 (de) * 1999-01-22 2000-05-25 Goldwell Gmbh Verwendung eines Mittels zum Behandeln von menschlichen Haaren
DE19902529A1 (de) * 1999-01-22 2000-08-03 Goldwell Gmbh Haarbehandlungsmittel
EP1295599A1 (en) * 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Method for the treatment of prevention of atopic dermatitis
MY177591A (en) 2006-10-16 2020-09-22 Lion Corp Nk1 receptor antagonist composition
SG183878A1 (en) * 2010-03-19 2012-10-30 Oxygen Biotherapeutics Inc Perfluorocarbon eye cream formulations
RU2443439C2 (ru) * 2010-05-05 2012-02-27 Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") Способ лечения красного плоского лишая
US8513309B2 (en) 2010-10-01 2013-08-20 Oxygen Biotherapeutics, Inc. Perfluorocarbons for use in treating pruritus
BR112015006051A2 (pt) 2012-10-11 2017-07-04 Nerre Therapeutics Ltd usos inéditos
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
CA2956022A1 (en) * 2014-07-24 2016-01-28 Plus Vitech,S.L Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772431A (en) * 1972-09-21 1973-11-13 W Mlkvy Effervescent mouthwash tablet
US3888976A (en) * 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
US4477439A (en) * 1981-04-13 1984-10-16 Walter J. Monacelli Treatment of irritated and excoriated areas around the stoma of ostomy patients
WO1983001252A1 (en) * 1981-10-09 1983-04-14 Hakanson, Rolf A drug based on a substance p antagonist
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
DE3584837D1 (de) * 1985-10-08 1992-01-16 Psori Med Ag Salzmischung zur behandlung der schuppenflechte (psoriasis) und anderer hautkrankheiten.
US4986981A (en) * 1986-07-07 1991-01-22 Den Mat Corporation Toothpaste having low abrasion
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
SE8701372L (sv) * 1987-04-02 1988-10-03 Boliden Ab Foerfarande och medel foer konservering av hoe
DE3929411A1 (de) * 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
CA2014201A1 (en) * 1989-04-26 1990-10-26 Albemarle Corporation Solid non-hygroscopic trialkylamine oxides
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
WO1991012266A1 (en) * 1990-02-15 1991-08-22 Fujisawa Pharmaceutical Co., Ltd. Peptide compound
AU664188B2 (en) * 1991-07-05 1995-11-09 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
CA2110725A1 (en) * 1991-07-10 1993-01-21 Andrew P. Owens Aromatic compounds, compositions containing them and their use in therapy
DK0607164T3 (da) * 1991-09-26 2002-06-17 Pfizer Kondenserede tricykliske nitrogenholdige heterocykliske forbindelser som substans P-receptorantagonister
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
JPH05339240A (ja) * 1992-06-04 1993-12-21 Yamanouchi Pharmaceut Co Ltd テトラヒドロイソキノリンアミド誘導体
DE9211006U1 (de) * 1992-08-17 1993-12-16 Kao Corporation GmbH, 40472 Düsseldorf Mittel zur Haarbehandlung
JPH06199892A (ja) * 1992-09-14 1994-07-19 Takeda Chem Ind Ltd Ｔａｎ−１６６６関連化合物
GB9222486D0 (en) * 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation

Also Published As

Publication number Publication date
JPH08208506A (ja) 1996-08-13
US5679360A (en) 1997-10-21
EP0717997A1 (fr) 1996-06-26
FR2728265A1 (fr) 1996-06-21
PL311916A1 (en) 1996-06-24
ATE204177T1 (de) 2001-09-15
FR2728265B1 (es) 1997-02-07
CA2165520C (fr) 2002-12-17
ES2160680T3 (es) 2001-11-16
HUT74746A (en) 1997-02-28
AR000509A1 (es) 1997-07-10
CA2165520A1 (fr) 1996-06-20
EP0717997B1 (fr) 2001-08-16
US20020068072A1 (en) 2002-06-06
HU9503624D0 (en) 1996-02-28
HU218921B (hu) 2000-12-28
DE69522188T2 (de) 2001-11-29
BR9505382A (pt) 1997-10-28
RU2146519C1 (ru) 2000-03-20
DE69522188D1 (de) 2001-09-20

Similar Documents

Publication Publication Date Title
MX9505181A (es) Utilizacion de un antagonista de la substancia p en una composicion farmaceutica para tratar desordenes de la piel de origen neurogenico.
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
ES2194308T3 (es) Utilizacion de sustancias con una actividad de oxitocina en la preparacion de medicamentos para la curacion de heridas.
CY2439B1 (en) Alpha-TNF antagonists in a cosmetic, pharmaceutical or dermotological composition.
DE69512374D1 (de) Zusammensetzungen, die troxerutin als komplex mit phosphatidylcholin enthalten, zur topischen behandlung von erektionsimpotenz
AR002974A1 (es) Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista.
MY132705A (en) Novel compounds with analgesic effect
FI973492A (fi) NO-syntaasin estäjät
GEP20012442B (en) Irreversible Inhibitors of Tyrosine Kinases
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
DE3485229D1 (de) Shampoo-praeparate.
MX9306295A (es) Composiciones farmaceuticas para tratar sintomas de resfriado.
ZA963959B (en) Tetralin compounds with improved mdr activity
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
BR9509006A (pt) Composiçao para aplicaçao tópica na pele composiçao farmacêutica uso de um inibidor de síntese de colesterol e processo para o tratamento mitigaçao ou prevençao de distúrbios de pele
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
SE8700467L (sv) Monoklonala humanantikroppberedningar som er korsprotektiva
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
CA2235038A1 (fr) Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
MX9601151A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento de liquenes y prurito y composicion obtenida.
ATE201823T1 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
MD1521F2 (en) Methods of thrombus forming inhibition, methods of treatment of thrombotic states, pharmaceutical compositions and kit for treatment of thrombotic states
NZ326345A (en) Composition containing diosgenin
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees